Abstract: A polyurethane foam wound dressing and a method for making the dressing is described. The dressing is made from the reaction of a polyurethane prepolymer with a difunctional cross-linking agent in the presence of DMEA and substantial amounts of water. The resulting dressing has a glazed, mirror-smooth surface for application to the wounded area and an insular region to maintain the wound at near body temperature. The dressing has a moisture vapor transmission rate that is close to the capacity of the wound surface to produce serous exudate.

Abstract: A delivery device is disclosed for delivering a beneficial agent to an animal. The device comprises a wall housing an internal space, a beneficial agent in the space, expandable means in the space for causing the beneficial agent to be delivered from the device and means in the space for shielding the beneficial agent from fluid.

Abstract: A transdermal drug delivery system with a dual permeation enhancer is described. The transdermal system comprises a body that contains supplies of drug and a dual permeation enhancer comprising sucrose cocoate and methyl laurate, and has a basal surface that contacts an area of skin and transmits the drug and the dual permeation enhancer to the area for absorption thereby. A method for coadministering a drug and a dual permeation enhancer comprising sucrose cocoate and methyl laurate is also described.

Abstract: Method and device for treating angina pectoris and preventing tolerance to nitrate drugs which takes into account the frequent need to provide the patient with relief from or prevention of pre-waking or early morning angina.

Abstract: A pharmaceutical composition for the treatment of cardiac arrhythmia comprising an effective amount of propafenone in combination with a subtherapeutic amount of quinidine, such that the quinidine potentiates the elimination half-life of the propafenone.The invention also comprises a method for treating patients with cardiac arrhythmia by means of administering said pharmaceutical composition.

Abstract: A solid dosage form having a fill composition encased in a shell composition; the fill composition comprising(a) 5-60 mg of nifedipine;(b) a 5-7 membered cyclic pharmaceutically acceptable ingestible carbonate of the formula ##STR1## where A is an alpha,omega-C.sub.2 -C.sub.4 alkylene which is unsubstituted or substituted by at least one C.sub.1 -C.sub.4 alkyl; and(c) a pharmaceutically acceptable ingestible surfactant having a total of d ring members and being of the formula ##STR2## wherein B is a C.sub.1-4 -alpha,omega-alkylene;n is an integer from 0 up to d-1;m is an integer from 0 up to (d-n-1);each R is independently H or a C.sub.1-4 alkyl which is unsubstituted or substituted by at least one R';each R' is independently a hydroxy which is free, etherified by R.sup.2, or esterified by R.sup.3 ;each R.sup.2 is a C.sub.2-4 straight or branched oxyalkylene or a poly (C.sub.2-4 straight or branched oxyalkylene), the terminal oxygen of which is bound to hydrogen or R.sup.3 ; and each R.sup.

Abstract: A dermal pharmaceutical preparation comprising a soft support having provided thereon a pressure-sensitive adhesive layer containing a pressure-sensitive adhesive and a drug, wherein said pressure-sensitive adhesive is a copolymer comprising a (meth)acrylamide having an amino group as a comonomer unit. The preparation remains the drug in a dissolved state and is excellent in drug liberation and adhesion to the skin.

Abstract: An osmotic device is disclosed comprising a first composition, and a second composition with the beneficial drug isradipine in the first composition.

Abstract: A cleansing and disinfecting composition comprising an alkaline per-salt and a positively charged phase-transfer agent. The composition preferably also contains a surfactant. The alkaline per-salt is an alkaline water-soluble salt having hydrogen peroxide of crystallization. The positively charged phase-transfer agent is preferably a quaternary ammonium salt. The composition may be formulated as a cream, aa bulk powder, a solution or tablets. It may also be incorporated in wipes, sponges and brushes. The compositions of this invention find utility in health care, as disinfectants in surgical applications, and as decontaminating agents. Specific uses include skin cleansing and disinfecting, treatment for exposure to toxic plants such as poison ivy, treatment for exposure to industrial and agricultural chemicals such as herbicides and pesticides, and cleansing and disinfecting surfaces and sensitive equipment.

Abstract: A transdermal delivery system suitable for the drug (4aR-trans )-3,4,4a,5,6,10b-hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol over an extended period of time is described.

Abstract: A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with sucrose monolaurate or a mixture of sucrose esters of coconut fatty acids, which is predominantly sucrose monolaurate. Preferred embodiments of therapeutic systems for delivering the drug and the sucrose ester employ a matrix containing drug at a concentration above saturation.

Abstract: An external dermatological composition containing a drug supply layer carried on a support and containing 5% to 35% by weight of ketoprofen in an acrylic or methacrylic copolymer, which copolymer is composed of (i) 0.5% to 11.0% by weight of an .alpha.,.beta.-unsaturated carboxylic acid or its anhydride, (ii) 0.1% to 28.0% by weight of a vinyl monomer, (iii) 1.0% to 5.5% by weight of a hydroxy C.sub.2 -C.sub.4 alkyl ester of acrylic or methacrylic acid, and (iv) a balance of a C.sub.4 -C.sub.18 alkyl ester of acrylic or methacrylic acid, and has a glass transition point of -15.degree. C. to -70.degree.C.

Abstract: The residence time in the human stomach of pharmaceutical, gastric controlled release, solid units can be increased significantly if the units have a density that is much higher than normal. A preferred oral dosage form according to the invention comprises a capsule or other dosage form having a dimension above 2 mm and that contains one or more of the said units. The density of each unit is preferably at least 2.5 and usually at least 2.7 g/ml and can conveniently be achieved by including at least 50% by weight of a weighting agent such as barium sulphate.

Abstract: A dosage form is disclosed comprising a coat that surrounds a drug. The coat comprises a subcoat and an overcoat thermally annealed to provide a single unit coat around the drug.

Abstract: A novel dosage form for drug active agents, reagents or other active agents comprising a film-like carrier material having an active agent-containing coating one side thereof and wherein the carrier material is in the form of a release paper, film or foil, and the active agent-containing coating is removed in a dosewise manner from the carrier material after subdivision into dosage units. The removed active agent-containing portions are suitable as oral drugs, pharmaceuticals, reagents or foodstuff.

Abstract: Pharmaceutical compositions for the prophylaxis and therapy of biliary tract calculosis and of biliary dyspepsia, containing as the active principle taurohyodeoxycholic acid, are herein described.

Abstract: A diffusional drug delivery device is described which can provide shelf life stability of the system components, elimination of the initial burst of drug and hence irritation, delayed onset of therapeutic effect and delivery of a therapeutic agent at an optimum rate. A metal layer and an activating means are inert when dry. Moisture activates the system whereby the activating means provides release of an eroding agent which erodes the metal layer through which the therapeutic agent diffuses and is subsequently delivered.

Abstract: This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer having the structural formula ##STR1## wherein X may represent sulfur, oxygen or nitrogen; a and b may be 0 or 1, c may be 0, 1 or 2, except that when X is oxygen, a, b and c are 0, when X is nitrogen c is 0 and only one of a or b is 1, and when X is sulfur a and b are 0; A is a branched or a straight chain, divalent aliphatic radical having from 0 to 2 double bonds; R' is selected from the group consisting of H, a lower alkyl group having from 1 to 4 carbon atoms, phenyl, lower alkyl or halogen substituted phenyl, acetamido, halogen, piperidinyl, lower alkyl or halogen substituted piperidinyl, carboalkoxy, carboxamide, and alkanoyl; and R is hydrogen or a lower alkyl group having from 1 to 4

Abstract: The invention relates to controlled release pharmaceutical compositions. These contain as active ingredient valproic acid, a salt of valproic acid, an ester of valproic acid, Valpromide, or any other pharmaceutically acceptable derivative of valproic acid which upon administration to humans provides a serum level of valproic acid, in combination with an additive which is selected from physiologically acceptable polymeric substances and from native proteins. The active ingredient is usually in the range of from 10 to 80 weight percent. The novel pharmaceutical compositions are prepared by applying a high pressure to a mixture of the ingredients. They result in a prolonged serum level of the active ingredient.

Abstract: A pharmaceutical composition for the transdermal delivery of loratadine comprising isopropyl myristate and rosemary oil and the method of using such a composition for the treatment of allergic reactions are disclosed.